Hologic, Inc. (NASDAQ:HOLX) Holdings Cut by Mawer Investment Management Ltd.

Mawer Investment Management Ltd. lowered its position in Hologic, Inc. (NASDAQ:HOLX) by 0.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,156,037 shares of the medical equipment provider’s stock after selling 5,198 shares during the quarter. Mawer Investment Management Ltd.’s holdings in Hologic were worth $84,194,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in the business. Oregon Public Employees Retirement Fund increased its stake in shares of Hologic by 138.5% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 49,572 shares of the medical equipment provider’s stock valued at $3,610,000 after purchasing an additional 28,783 shares during the period. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Hologic in the fourth quarter valued at approximately $249,000. OmniStar Financial Group Inc. increased its stake in shares of Hologic by 3.3% in the fourth quarter. OmniStar Financial Group Inc. now owns 6,300 shares of the medical equipment provider’s stock valued at $459,000 after purchasing an additional 200 shares during the period. CI Investments Inc. acquired a new stake in shares of Hologic in the fourth quarter valued at approximately $501,000. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its stake in shares of Hologic by 4.2% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 75,336 shares of the medical equipment provider’s stock valued at $5,487,000 after purchasing an additional 3,070 shares during the period. Institutional investors own 92.43% of the company’s stock.

Several brokerages have commented on HOLX. Raymond James restated a “buy” rating on shares of Hologic in a research note on Wednesday, January 6th. Morgan Stanley raised their price objective on shares of Hologic from $80.00 to $84.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 15th. UBS Group raised their price objective on shares of Hologic from $77.00 to $81.00 and gave the company a “neutral” rating in a research note on Thursday, November 5th. Smith Barney Citigroup raised their price objective on shares of Hologic from $90.00 to $85.00 in a research note on Thursday, November 5th. Finally, Argus raised their price objective on shares of Hologic from $85.00 to $100.00 in a research note on Tuesday, December 8th. Five equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Hologic currently has a consensus rating of “Buy” and a consensus price target of $81.00.

In related news, insider Benjamin Jordan Cohn sold 8,396 shares of the firm’s stock in a transaction on Thursday, February 4th. The stock was sold at an average price of $84.31, for a total value of $707,866.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kevin R. Thornal sold 16,869 shares of the firm’s stock in a transaction on Thursday, December 10th. The stock was sold at an average price of $73.99, for a total value of $1,248,137.31. Following the completion of the transaction, the insider now directly owns 40,849 shares of the company’s stock, valued at $3,022,417.51. The disclosure for this sale can be found here. Company insiders own 1.00% of the company’s stock.

Shares of Hologic stock traded up $1.58 during midday trading on Tuesday, hitting $76.15. The company had a trading volume of 48,948 shares, compared to its average volume of 2,115,238. The business’s 50 day simple moving average is $78.89 and its two-hundred day simple moving average is $70.84. The stock has a market cap of $19.62 billion, a PE ratio of 17.75, a P/E/G ratio of 0.62 and a beta of 1.27. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.79 and a quick ratio of 1.47. Hologic, Inc. has a 1-year low of $26.49 and a 1-year high of $85.00.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, January 27th. The medical equipment provider reported $2.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.14 by $0.72. The business had revenue of $1.61 billion for the quarter, compared to the consensus estimate of $1.39 billion. Hologic had a net margin of 29.53% and a return on equity of 45.24%. Hologic’s quarterly revenue was up 89.3% on a year-over-year basis. During the same quarter last year, the company posted $0.61 earnings per share. On average, sell-side analysts expect that Hologic, Inc. will post 7.17 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.

See Also: Capital Gains Distribution

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.